OncoC4, a clinical-stage biotechnology company developing cancer and immunology treatments, has appointed Dan Janiak, Ph.D., as Chief Business Officer.
Janiak brings more than 15 years of experience in biotechnology financing, corporate strategy, business development, venture investing, and company formation.
In his new role, he will oversee business development initiatives and help shape OncoC4’s corporate strategy as the company advances its portfolio of investigational therapies.
Janiak most recently served as Executive Director, Business Development at AstraZeneca, where he led oncology-related platform transactions involving artificial intelligence, machine learning, and other enabling technologies.
Previously, he served as president and chief operating officer of Trotana Therapeutics.
Before that, he was the first employee of Taysha Gene Therapies, where he became senior vice president of corporate strategy and business development and helped establish the company.
His earlier career included corporate development and strategic positions at VelosBio and AveXis.
Janiak began his career in venture investing and company formation at Mercury Fund and In-Q-Tel, working with emerging biotechnology and medical technology companies.
At OncoC4, he joins an organization developing several oncology and immunology programs.
Its pipeline includes cesalatamig, an investigational PD-1/VEGF bispecific antibody undergoing development across multiple cancer indications.
The company is also developing tasafustobart, an anti-SIGLEC-10 antibody being evaluated in oncology and neurological indications.
Another program, ONC-783, is a T-cell engager targeting a CD24 epitope expressed in multiple cancers.
OncoC4 also maintains a collaboration with BioNTech to develop gotistobart, an investigational CTLA-4-targeting therapy being evaluated in solid tumors.
Janiak’s appointment strengthens the company’s ability to evaluate partnerships, financing opportunities, and strategic transactions as its development programs advance.
KEY QUOTES:
“We are delighted to welcome Dan to OncoC4 at an important stage in the Company’s growth. Dan brings a rare combination of scientific understanding, strategic judgment and transaction experience across both emerging biotechnology companies and global biopharmaceutical organizations. His experience building partnerships, executing complex transactions and developing corporate strategy will be highly valuable as we continue to advance our pipeline and pursue opportunities to maximize the value of our innovative therapies for patients.”
Yang Liu, Ph.D., Co-Founder, CEO And Chief Scientific Officer Of OncoC4
“OncoC4 has built a compelling portfolio of innovative oncology and immunology programs, and I am excited to join the company at this important point in its evolution. I look forward to working with Yang and the leadership team to advance OncoC4’s business development and corporate strategy, build strategic partnerships, and create opportunities that can accelerate the company’s programs and bring new therapies to patients.”
Dan Janiak, Ph.D., Chief Business Officer Of OncoC4

